Cargando…

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

BACKGROUND: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic inflammation, and inappropriately...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heaney, Liam G, Busby, John, Hanratty, Catherine E, Djukanovic, Ratko, Woodcock, Ashley, Walker, Samantha M, Hardman, Timothy C, Arron, Joseph R, Choy, David F, Bradding, Peter, Brightling, Christopher E, Chaudhuri, Rekha, Cowan, Douglas C, Mansur, Adel H, Fowler, Stephen J, Niven, Robert M, Howarth, Peter H, Lordan, James L, Menzies-Gow, Andrew, Harrison, Tim W, Robinson, Douglas S, Holweg, Cecile T J, Matthews, John G, Pavord, Ian D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783382/ https://www.ncbi.nlm.nih.gov/pubmed/32916135 http://dx.doi.org/10.1016/S2213-2600(20)30397-0

Ejemplares similares

Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
por: Busby, John, et al.
Publicado: (2022)

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
por: Hanratty, Catherine E., et al.
Publicado: (2018)

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
por: Heaney, Liam G, et al.
Publicado: (2016)

Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability
por: Newby, Chris, et al.
Publicado: (2014)

Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma
por: Couillard, Simon, et al.
Publicado: (2021)

Benefits of specialist severe asthma management: demographic and geographic disparities
por: Redmond, Charlene, et al.
Publicado: (2022)

Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker‐high and ‐low severe asthma
por: Khalfaoui, Latifa, et al.
Publicado: (2022)

Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry
por: Heaney, Liam G, et al.
Publicado: (2010)

Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry
por: Sweeney, Joan, et al.
Publicado: (2012)

Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
por: Jackson, David J, et al.
Publicado: (2021)

Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)
por: Niven, Robert M, et al.
Publicado: (2016)

Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus
por: Gallagher, Nicola E., et al.
Publicado: (2018)

ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma—implications for COVID-19
por: Bradding, Peter, et al.
Publicado: (2020)

Advancing Understanding of Mechanisms of Severe Asthma and Drug Effects Using Transcriptomics
por: Djukanović, Ratko
Publicado: (2019)

Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
por: Barnes, Neil, et al.
Publicado: (2013)

Early-phase clinical trials in a pandemic: learning from the response to COVID-19
por: Horsley, Alex, et al.
Publicado: (2022)

Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy
por: Butler, Claire A., et al.
Publicado: (2021)

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Primary Human Airway Epithelial Cell-Dependent Inhibition of Human Lung Mast Cell Degranulation
por: Martin, Neil, et al.
Publicado: (2012)

Adenosine closes the K(+) channel K(Ca)3.1 in human lung mast cells and inhibits their migration via the adenosine A(2A) receptor
por: Duffy, S Mark, et al.
Publicado: (2007)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma
por: Bilocca, David, et al.
Publicado: (2017)

Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes
por: Gupta, Sumit, et al.
Publicado: (2010)

Body Mass and Fat Mass in Refractory Asthma: An Observational 1 Year Follow-Up Study
por: Bafadhel, Mona, et al.
Publicado: (2010)

Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma
por: Bauer, Rebecca N, et al.
Publicado: (2019)

Long‐term corticosteroid use, adrenal insufficiency and the need for steroid‐sparing treatment in adult severe asthma
por: Gurnell, M., et al.
Publicado: (2021)

Engagement of the EP(2) prostanoid receptor closes the K(+) channel K(Ca)3.1 in human lung mast cells and attenuates their migration
por: Duffy, S Mark, et al.
Publicado: (2008)

The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?
por: Smith, Steven J., et al.
Publicado: (2021)

Difficult‐to‐treat asthma patients from ethnic minority groups in central England are at an enhanced risk of house dust mite sensitisation
por: Mansur, Adel H., et al.
Publicado: (2023)

Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study
por: Shrine, Nick, et al.
Publicado: (2019)

Functional K(Ca)3.1 K(+) channels are required for human fibrocyte migration
por: Cruse, Glenn, et al.
Publicado: (2011)

Definitions of non-response and response to biological therapy for severe asthma: a systematic review
por: Khaleva, Ekaterina, et al.
Publicado: (2023)

Large scale clinical trials: lessons from the COVID-19 pandemic
por: Horsley, Alex R, et al.
Publicado: (2022)

Interleukin-13 in Asthma and Other Eosinophilic Disorders
por: Doran, Emma, et al.
Publicado: (2017)

Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA)
por: Lanario, Joseph W., et al.
Publicado: (2020)

In vitro, in silico and in vivo study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss
por: Chernyavsky, Igor L., et al.
Publicado: (2018)

Persistence of oxidant and protease burden in the airways after smoking cessation
por: Louhelainen, Noora, et al.
Publicado: (2009)

Tensin1 expression and function in chronic obstructive pulmonary disease
por: Stylianou, Panayiota, et al.
Publicado: (2019)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

Lung Topology Characteristics in patients with Chronic Obstructive Pulmonary Disease
por: Belchi, Francisco, et al.
Publicado: (2018)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
por: Pavord, Ian, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_0k0ie8b57bf1hrmfo3pqb3anpo